ATRA (Atara Biotherapeutics) Total Assets: $20.00 Mil (As of Mar. 2026)


ATRA Atara Biotherapeutics Inc ATRA
29 GF Score
Price $10.71
GF Value $1.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Total Assets?

Atara Biotherapeutics ATRA +2.54% 29 Total Assets is $20.00 Mil as of Mar. 2026. GuruFocus rates ATRA with a GF Score™ of 29/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Atara Biotherapeutics's Total Assets for the quarter that ended in Mar. 2026 was $20.00 Mil.

During the past 12 months, Atara Biotherapeutics's average Total Assets Growth Rate was -75.90% per year. During the past 3 years, the average Total Assets Growth Rate was -55.50% per year. During the past 5 years, the average Total Assets Growth Rate was -27.70% per year. During the past 10 years, the average Total Assets Growth Rate was 16.40% per year.

During the past 13 years, Atara Biotherapeutics's highest 3-Year average Total Assets Growth Rate was 278.30%. The lowest was -55.50%. And the median was 19.20%.

Total Assets is connected with ROA %. Atara Biotherapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -82.42%. Total Assets is also linked to Revenue through Asset Turnover. Atara Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.03.

Atara Biotherapeutics  (NAS:ATRA) Total Assets Explanation

Total Assets is connected with ROA %.

Atara Biotherapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-16.58/( (20.235+19.997)/ 2 )
=-16.58/20.116
=-82.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Atara Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.516/( (20.235+19.997)/ 2 )
=0.516/20.116
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Atara Biotherapeutics Total Assets Related Terms

Atara Biotherapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Total Assets Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 468.13 376.42 165.50 109.10 20.24

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.04 36.90 30.17 20.24 20.00
ATRA
29GF Score
Atara Biotherapeutics Inc ATRA
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Atara Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-38.502+58.737
=20.24

Atara Biotherapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=-37.312+57.309
=20.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $20.00 Mil mean?
Atara Biotherapeutics (ATRA) has a Total Assets of $20.00 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Total Assets too high?
Atara Biotherapeutics' current Total Assets is $20.00 Mil. Overall, Atara Biotherapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Total Assets compare to ANIX and BMEA?
Atara Biotherapeutics' Total Assets of $20.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Total Assets is $20.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $10.71 — trading 586.5% above its estimated fair value. The current Total Assets is $20.00 Mil. Atara Biotherapeutics' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Total Assets is $20.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $10.71 is trading 586.5% above its estimated GF Value™ of $1.56. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • Total Assets: $20.00 Mil
  • GF Value™: $1.56 vs. price of $10.71 (586.5% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
29GF Score

Get the complete analysis for ATRA

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.71
Price
$1.56
GF Value